Post-doctorat
Project Context: Diabetes is a growing threat to global health, affecting 463 million people worldwide in 2019, or 1 in 11 adults. The World Health Organization predicts that 578 million people will suffer from diabetes in 2030. Diabetes, type 1 or 2, causes an abnormal and prolonged increase in blood glucose levels, mainly caused by deficiency or failure to use insulin. In the long term, diabetes can lead to many complications, including vasculopathy, neuropathy, retinopathy, and diabetic foot ulcers.
Cell replacement therapy is possible for some patients, called pancreatic islet transplantation, which has recently been accepted into routine care by the French “Haute Autorité de Santé”. Despite the effectiveness of this therapy, some weaknesses remain, highlighting the need for a relevant human model to understand the decline of pancreatic islet transplants in order to finely-tune the treatment for each grafted patient.
In this context, we aim at personalized medicine for T1D patients’ ongoing pancreatic islet transplantation.
Project Description: The candidate will be using native human islets and will be involved in the cryopreservation of native islets, islet-on-chip experiments, and immunity assessment with the patient’s samples to address the personalized medicine challenges. The candidate will work closely with our research team and collaborate with our partners (CEA Leti, CHU Grenoble). The candidate will perform cell culture, microfluidics, transcriptomics analysis, image analysis, and quantification.
Candidate Profile:
Grenoble
01/01/2025
2024-32782
Laboratory: BIOMICS LAB, IRIG, CEA Grenoble (UGA/Inserm/CEA), 17 avenue des Martyrs, 38 054 Grenoble, France. Head of lab: Xavier Gidrol.
We conduct complementary scientific and technological work and coordinate our research to implement our global scientific project aiming at the identification of biomarkers and therapeutic targets, the study of their function, their use for diagnosis, and for the development of new therapeutic solutions in the form of drug candidates or biotherapies derived from cell and tissue engineering, as well as tools for bioinformatics analysis of experimental data, mainly in metabolic diseases and cancer.